Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

211results about How to "Improve anti-tumor efficacy" patented technology

Common carrier material for targeting anticancer drug and gene and preparation and application

The invention relates to a common carrier material based on graphene oxide for a targeting anticancer drug and a gene and application and application. Folic acid, lactobionic acid and other tumor cell targeting or liver targeting molecules and part of amino groups of soluble chitosan are connected by amide bonds to prepare a conjugate, the conjugate is then connected with graphene oxide, quaternization is performed by using an epoxy compound with a quaternary ammonium group, and gene molecules are loaded by the quaternizationquaternized part of the chitosan through electrostatic attraction; and then the anticancer drug is loaded by pi-pi conjugates, hydrogen bonds and hydrophobic effects in a non-covalent bond method. By adopting the targeting performance of targeting molecules and effects of graphene oxide of a particular size to enhance penetration and retention in tumor tissues and combining the performance of the graphene oxide for pH response control release of the loaded drug, the drug can be realized released in a tumor cell, an intelligent delivery system for the common carrier of the tumor targeting or liver targeting anticancer drug and the gene is synthesized from the perspective of synergetic medication, and a theoretical basis and a method basis are provided for combined therapy of tumor.
Owner:TIANJIN MEDICAL UNIV

Stapled-RGD polypeptide, and applications thereof in tumor targeting delivery

The invention belongs to the field of pharmacology, and relates to stapled-RGD polypeptide, and applications thereof in tumor targeting delivery. Multifunctional targeting polypeptide molecule stapled-RGD with high combination activity with integrin and biological membrane barrier penetration capacity is designed and prepared based on binding peptide cyclization technology; and preparation of fluorescein, drugs, and high molecule carriers modified by the multifunctional targeting polypeptide molecule stapled-RGD, and applications of the fluorescein, the drugs, and the high molecule carriers in tumor imaging and construction of targeted therapy targeted drug delivery systems are disclosed. It is shown by results that specific uptaking of model drugs carried by stapled-RGD by positive cells, tumor mimicry vessels, and tumor ball tissues of expressed integrin is realized, higher tumor targeting capacity, imaging functions, and membrane barrier cell penetration capacity are achieved; nano targeted drug delivery systems constructed by the high molecule carriers modified by stapled-RGD can be used for delivering carried model drugs to target tissues, antitumor drug effect is improved obviously; and stapled-RGD possesses a promising application prospect in mediating drugs, nano targeted drug delivery system membrane barrier penetration, active target searching, tumor diagnosis, and targeted therapy.
Owner:FUDAN UNIV

Injection Cu(DDC)2 protein nano-particle preparation used for treating tumor, and preparation method thereof

InactiveCN103222961ALittle discomfortShort hospital stayOrganic active ingredientsPowder deliverySolubilityMelanoma
A compound Cu(DDC)2 with relatively high tumor-inhibiting activity can be used for treating cancers such as melanoma, breast cancer, lung cancer, liver cancer, and the like. The treatment effect is broad, and the compound has certain selective killing effect against tumor cells. The invention relates to an Cu(DDC)2 injection protein nano-particle preparation used for treating tumor, and a preparation method thereof. Therefore, problems of poor water-solubility and difficulty in intravenous administration of Cu(DDC)2 are solved. According to the invention, with an ultrasonic method, a high-pressure homogenization method, and a micro-jet method, the Cu(DDC)2 injection protein nano-particles are prepared. The Cu(DDC)2 protein nano-particles are prepared from the components that (Cu(DDC)2 + organic solvent) :(protein + water) = 1:2-1:30, wherein the specification of Cu(DDC)2 is 0.01-5mg/mL, the specification of protein is 0.05-25% (w/v), and a ratio of organic solvent to water is 1:2-1:30. Proteins such as human serum albumin (HSA), bovine serum albumin (BSA), hydrophobic protein, glycoprotein, and lipoprotein or polypeptide is adopted as a carrier and a stabilizer for coating medicine particles, such that the particles have good biocompatibility and high security. Cu(DDC)2 tumor-inhibiting treatment effect is improved, and adverse reaction is reduced.
Owner:SHENYANG PHARMA UNIVERSITY

Tumor targeting polypeptide-medicine coupling derivative, and preparation method and application thereof

The invention belongs to the technical field of biological pharmacy, and relates to a tumor targeting polypeptide-medicine coupling derivative, and a preparation method and application thereof. The tumor targeting polypeptide-medicine coupling derivative comprises targeting polypeptides, long effect polypeptides and medicine molecules, wherein the targeting polypeptides are connected onto the endC of the long effect polypeptides through flexible connecting peptides; fusion peptides are used as carriers of the medicine molecules; the medicine carriers and the long effect polypeptides in the fusion peptides are connected through chemical bonds; and the long effect polypeptides are polypeptide or protein structural domains having the affine mutual effects with human serum albumin. The tumortargeting polypeptide-medicine coupling derivative can be combined with the human serum albumin; the remaining half-life period in the blood circulation system can be obviously prolonged; the long-term effectiveness in the body is realized; the targeting and seepage into the tumor tissues or cells can be realized; then, free effect molecules are released in tumor tissue micro acid environments orin cells in through an acid hydrolysis mechanism; and a better anti-tumor efficiency is achieved.
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI

Application of ursolic-acid nano medicine-carrying microspheres for treating tumors and preparation

InactiveCN102670525AExtend cycle timeExcellent anti-tumor efficacyPowder deliveryOrganic active ingredientsMpeg plgaPolyethylene glycol
The invention relates to the application of ursolic-acid nano medicine-carrying microspheres for treating tumors. The ursolic-acid nano medicine-carrying microspheres contain ursolic acid and a medicine-carrying material which are mixed, wherein the medicine-carrying material is a biparental segmented copolymer synthesized by one of polycaprolactone, polylactic acid or polyglycolic acid and polyethylene glycol, i.e. polycaprolactone-polyethylene glycol (mPEG-PCL), polylactic acid-polyethylene glycol (mPEG-PLA) or polyglycolic acid-polyethylene glycol (mPEG-PLGA); and the ursolic-acid nano medicine-carrying microspheres comprise 5 to 35wt% of ursolic acid and 65 to 95wt% of medicine-carrying material which are mixed.
Owner:李晓林

Cabazitaxel lipid microsphere injection and preparation method thereof

InactiveCN104306333AGood dilution resistanceAvoid drug wasteOrganic active ingredientsMacromolecular non-active ingredientsDrugChemistry
The invention relates to a cabazitaxel lipid microsphere injection and a preparation method thereof. The injection comprises the following components in percentage by weight: 0.01% to 1 % of cabazitaxel cholesterol complex (based on cabazitaxel), 5% to 30% of oil for injection; 1% to 6% of phospholipid for injection, 0.2% to 0.7% of auxiliary emulsifier, 0.05% to 1.0% of amphiphilic polyamino, 2.0% to 3.5% of osmotic pressure modifier, the balance being water for injection. The cabazitaxel lipid microsphere injection is prepared by using phospholipid as an emulsifier, a surfactant as a coemulsifier, and high-purity cabazitaxel as an active ingredient, and adding cholesterol, amphiphilic polyamino acids, an osmotic pressure modifier and water for injection through an ultrahigh pressure microjet nano-dispersion technology. By means of the unique interaction of cholesterol and drugs, the chemical stability of cabazitaxel in lipid microspheres is improved, and the thermodynamic stability of cabazitaxel in the lipid microspheres is also improved. The stability of a preparation is further enhanced by adding the amphiphilic polyamino acids provided by the invention.
Owner:SHENYANG PHARMA UNIVERSITY

Folate-conjugated polyethylene glycol monostearate, and preparation method and application thereof

The invention discloses folate-conjugated polyethylene glycol monostearate, and a preparation method and application thereof. The folate-conjugated polyethylene glycol monostearate has a structure shown as below, wherein n equals to 45-136. The preparation method of the folate-conjugated polyethylene glycol monostearate comprises the following steps: weighing folic acid and triethylamine; adding dimethylsulfoxide for dissolution; adding dicyclohexylcarbodiimide and N-hydroxy succinimide; stirring at room temperature by avoiding light; standing for overnight; filtering to remove by-products; then adding polyethylene glycol monostearate; heating to dissolve; reacting overnight to obtain a coarse product; placing the coarse product in a dialysis bag; dialyzing with water; and conducting freeze-drying to obtain the folate-conjugated polyethylene glycol monostearate. The folate-conjugated polyethylene glycol monostearate can be applied to preparation of a folic acid modified antitumor drug delivery system, improve drug targeting, efficacy and pharmacokinetics, and reduce toxicity.
Owner:HANGZHOU NORMAL UNIVERSITY

Fusion immunomodulatory proteins and methods for making same

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
Owner:BIOCON LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products